Athersys, Inc. (NASDAQ:ATHX) shares rose 6.3% during trading on Tuesday . The company traded as high as $1.90 and last traded at $1.86. Approximately 1,387,674 shares changed hands during trading, an increase of 107% from the average daily volume of 671,245 shares. The stock had previously closed at $1.75.

ATHX has been the subject of a number of research analyst reports. Zacks Investment Research lowered shares of Athersys from a “buy” rating to a “hold” rating in a research report on Wednesday. Maxim Group reaffirmed a “buy” rating on shares of Athersys in a research report on Wednesday, May 10th.

The company’s 50-day moving average price is $1.63 and its 200 day moving average price is $1.48. The company’s market capitalization is $233.52 million.

Athersys (NASDAQ:ATHX) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). The company had revenue of $0.67 million during the quarter, compared to analysts’ expectations of $0.96 million. Athersys had a negative net margin of 729.07% and a negative return on equity of 121.47%. The business’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.08) EPS. On average, equities research analysts forecast that Athersys, Inc. will post ($0.24) EPS for the current fiscal year.

In other news, EVP John J. Harrington sold 36,000 shares of the business’s stock in a transaction that occurred on Friday, June 16th. The shares were sold at an average price of $1.45, for a total value of $52,200.00. Following the completion of the transaction, the executive vice president now directly owns 712,743 shares in the company, valued at approximately $1,033,477.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 9.40% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Athersys by 9.4% in the 2nd quarter. Vanguard Group Inc. now owns 4,265,772 shares of the biopharmaceutical company’s stock valued at $6,441,000 after buying an additional 366,572 shares in the last quarter. State Street Corp raised its position in shares of Athersys by 27.2% in the 2nd quarter. State Street Corp now owns 1,432,695 shares of the biopharmaceutical company’s stock valued at $2,161,000 after buying an additional 305,944 shares in the last quarter. Northern Trust Corp raised its position in shares of Athersys by 30.8% in the 2nd quarter. Northern Trust Corp now owns 1,123,870 shares of the biopharmaceutical company’s stock valued at $1,697,000 after buying an additional 264,549 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Athersys by 35.2% in the 1st quarter. Geode Capital Management LLC now owns 756,004 shares of the biopharmaceutical company’s stock valued at $1,292,000 after buying an additional 196,981 shares in the last quarter. Finally, Royal Bank of Canada raised its position in shares of Athersys by 7,334.0% in the 2nd quarter. Royal Bank of Canada now owns 380,846 shares of the biopharmaceutical company’s stock valued at $576,000 after buying an additional 375,723 shares in the last quarter. Institutional investors own 19.08% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Athersys, Inc. (ATHX) Stock Price Up 6.3%” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.dailypolitical.com/2017/09/07/athersys-inc-athx-stock-price-up-6-3.html.

About Athersys

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.